Evaluating Technologies Found Cost Effective at Zero Price

This article explains why some technologies may fail to demonstrate cost effectiveness even when the acquisition price is set to zero, raising both methodological and ethical questions for health technology assessment (HTA) agencies. Learn more here. (Source: Sarah Davis, Dr. Ron Akehurst, Health Policy)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020
Scientific Research And Development Services Global Market… 06/19/2020
Jeff Anderson Joins OPEN Health as European Lead for OPEN VIE… 06/16/2020
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
Paying for Digital Health: Payer Insights (2019) 09/24/2019